Allergen immunotherapy in children and adolescents with respiratory diseases

Maria Angela Tosca; Amelia Licari; Roberta Olcese; Riccardo Castagnoli; Alessia Marseglia; Gian Luigi Marseglia; Michele Miraglia Del Giudice; Alberto Martelli; Mauro Calvani; Carlo Caffarelli; Marzia Duse; Claudio Cravidi; Fabio Cardinale; Giorgio Ciprandi

doi:10.23750/abm.v91i11-S.10309

Allergen immunotherapy in children and adolescents with respiratory diseases

Maria Angela Tosca, Amelia Licari, Roberta Olcese, Riccardo Castagnoli, Alessia Marseglia, Gian Luigi Marseglia, Michele Miraglia Del Giudice, Alberto Martelli, Mauro Calvani, Carlo Caffarelli, Marzia Duse, Claudio Cravidi, Fabio Cardinale, Giorgio Ciprandi

Research output: Contribution to journal › Review article › peer-review

Abstract

To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations. (www.actabiomedica.it).

Original language	English
Article number	e2020006
Pages (from-to)	1-4
Number of pages	4
Journal	Acta Biomedica
Volume	91
DOIs	https://doi.org/10.23750/abm.v91i11-S.10309
Publication status	Published - 2020

Keywords

Allergen-specific immunotherapy
Allergic asthma
Children
Subcutaneous immunotherapy
Sublingual immunotherapy

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.23750/abm.v91i11-S.10309

Fingerprint Dive into the research topics of 'Allergen immunotherapy in children and adolescents with respiratory diseases'. Together they form a unique fingerprint.

Cite this

Allergen immunotherapy in children and adolescents with respiratory diseases. / Tosca, Maria Angela ; Licari, Amelia; Olcese, Roberta; Castagnoli, Riccardo; Marseglia, Alessia; Marseglia, Gian Luigi; Del Giudice, Michele Miraglia; Martelli, Alberto; Calvani, Mauro; Caffarelli, Carlo; Duse, Marzia; Cravidi, Claudio; Cardinale, Fabio; Ciprandi, Giorgio.

In: Acta Biomedica, Vol. 91, e2020006, 2020, p. 1-4.

Research output: Contribution to journal › Review article › peer-review

Tosca, Maria Angela ; Licari, Amelia ; Olcese, Roberta ; Castagnoli, Riccardo ; Marseglia, Alessia ; Marseglia, Gian Luigi ; Del Giudice, Michele Miraglia ; Martelli, Alberto ; Calvani, Mauro ; Caffarelli, Carlo ; Duse, Marzia ; Cravidi, Claudio ; Cardinale, Fabio ; Ciprandi, Giorgio. / Allergen immunotherapy in children and adolescents with respiratory diseases. In: Acta Biomedica. 2020 ; Vol. 91. pp. 1-4.

@article{ef08ab61f03c42f58f80eb2348ff5c6c,

title = "Allergen immunotherapy in children and adolescents with respiratory diseases",

abstract = "To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations. (www.actabiomedica.it).",

keywords = "Allergen-specific immunotherapy, Allergic asthma, Children, Subcutaneous immunotherapy, Sublingual immunotherapy",

author = "Tosca, {Maria Angela} and Amelia Licari and Roberta Olcese and Riccardo Castagnoli and Alessia Marseglia and Marseglia, {Gian Luigi} and {Del Giudice}, {Michele Miraglia} and Alberto Martelli and Mauro Calvani and Carlo Caffarelli and Marzia Duse and Claudio Cravidi and Fabio Cardinale and Giorgio Ciprandi",

year = "2020",

doi = "10.23750/abm.v91i11-S.10309",

language = "English",

volume = "91",

pages = "1--4",

journal = "Acta Biomedica de l'Ateneo Parmense",

issn = "0392-4203",

publisher = "L'Ateneo Parmense",

}

TY - JOUR

T1 - Allergen immunotherapy in children and adolescents with respiratory diseases

AU - Tosca, Maria Angela

AU - Licari, Amelia

AU - Olcese, Roberta

AU - Castagnoli, Riccardo

AU - Marseglia, Alessia

AU - Marseglia, Gian Luigi

AU - Del Giudice, Michele Miraglia

AU - Martelli, Alberto

AU - Calvani, Mauro

AU - Caffarelli, Carlo

AU - Duse, Marzia

AU - Cravidi, Claudio

AU - Cardinale, Fabio

AU - Ciprandi, Giorgio

PY - 2020

Y1 - 2020

N2 - To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations. (www.actabiomedica.it).

AB - To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations. (www.actabiomedica.it).

KW - Allergen-specific immunotherapy

KW - Allergic asthma

KW - Children

KW - Subcutaneous immunotherapy

KW - Sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85092356275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092356275&partnerID=8YFLogxK

U2 - 10.23750/abm.v91i11-S.10309

DO - 10.23750/abm.v91i11-S.10309

M3 - Review article

AN - SCOPUS:85092356275

VL - 91

SP - 1

EP - 4

JO - Acta Biomedica de l'Ateneo Parmense

JF - Acta Biomedica de l'Ateneo Parmense

SN - 0392-4203

M1 - e2020006

ER -